

January 14, 2014

Seikagaku Corporation
(Securities Code: TSE 4548)

Seikagaku Announces Confirmation of Victory in the Gel-One® Patent Infringement Lawsuit

Seikagaku Corporation (Tokyo, Japan) hereby announces that Genzyme Corporation (Massachusetts, U.S.A.), the plaintiff in a patent infringement lawsuit concerning Gel-One®, a single-injection injectable treatment for osteoarthritis pain of the knee, withdrew an appeal filed in the United States Court of Appeals for the Federal Circuit. As a result, the victory of Seikagaku and Zimmer, Inc. (Indiana, U.S.A.) in the lawsuit was confirmed on January 13, 2014 (local time).

Genzyme filed the lawsuit in April 2011 in the United States District Court for the District of Massachusetts. After a full trial and jury verdict, the Court confirmed the judgment that Genzyme's patent claims are not valid and that there had been no patent infringement by Seikagaku and Zimmer. Genzyme filed an appeal of the ruling in the United States Court of Appeals for the Federal Circuit in October 2013. Genzyme withdrew the appeal, leaving the District Court judgment of invalidity and non-infringement as the final judgment.

Zimmer is the exclusive distributor of Gel-One® in the United States. Seikagaku will continue its collaborative efforts with Zimmer to achieve higher market penetration for Gel-One® in the U.S.

#####